Bausch & Lomb is one of the largest vision care companies in the US. Bausch spun off from its former parent company, Bausch Health, in 2022 and it now operates in three segments: vision care, surgical ...

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

According to iSpot.TV’s analysis of January TV drug ad spending data, Novartis’ prostate cancer drug Pluvicto swooped in to take the No. 1 spot on the list, with more than $47 million spent ...

Novartis AG (NYSE:NVS ... be it with Sandoz or a few years back, even with Alcon. This gives us also ample capacity, of course, to reinvest in the business pursue bolt-on deals and return ...

Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast. [Operator instructions] The conference is being recorded. [Operator ...

But Steinfeld is gearing up for another arena. Steinfeld is teaming up with pharmaceutical company Novartis to raise awareness about breast cancer with a bold and empowering commercial that will ...

To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s biggest stages. The drugmaker’s first-ever Super Bowl ad is set to ...

Existing investor F-Prime Capital also joined the round, with participation from new investors Novartis Venture Fund, RiverVest Venture Partners, funds managed by abrdn, Pictet Alternative ...

Are you a print subscriber? Activate your account. By Tim Nudd - 19 hours 17 min ago By Amir Farhang - 19 hours 17 min ago By Ashley Joseph - 1 day 17 hours ago By Ad Age Staff - 1 day 17 hours ...

Novartis AG’s plan to sell its 70.6% stake in Novartis India is on track, CEO Vas Narasimhan confirmed at the World Economic Forum in Davos. Speaking to CNBC-TV18, he emphasised the company’s ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...